Format

Send to

Choose Destination
J Virol. 2015 Apr;89(8):4681-4. doi: 10.1128/JVI.03485-14. Epub 2015 Feb 4.

Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions.

Author information

1
McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada.
2
McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada.
3
McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada mark.wainberg@mcgill.ca.

Abstract

The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections with DTG, using viruses resistant to older INSTIs and infectivity and resistance assays, and showed that the presence of the E92Q or N155H substitution was compatible with the emergence of R263K, whereas the G140S Q148R, E92Q N155H, G140S, Y143R, and Q148R substitutions were not.

PMID:
25653436
PMCID:
PMC4442391
DOI:
10.1128/JVI.03485-14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center